FDA Advisors Will Scrutinize CT Colonography Evidence
This article was originally published in The Gray Sheet
Executive Summary
Two FDA advisory panels will come together Sept. 9 to consider the latest evidence supporting computed tomography colonography as a general screening tool for colorectal cancer. The technique has been touted as a less invasive option to traditional colonoscopy, but its use has been strongly questioned due to risks from radiation exposure and false positives.